136 related articles for article (PubMed ID: 36474132)
1. Seromucinous and Mucinous Borderline Ovarian Tumors: We Need to Know More.
Laban M; Chen X; Guo B
Reprod Sci; 2023 May; 30(5):1684-1685. PubMed ID: 36474132
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Characteristics and Prognosis of 91 Patients with Seromucinous and Mucinous Borderline Ovarian Tumors: a Comparative Study.
Wu B; Li J; Tao X; Wang J; Zhu G; Lu X; Chen R
Reprod Sci; 2023 Jun; 30(6):1927-1937. PubMed ID: 36512190
[TBL] [Abstract][Full Text] [Related]
3. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract][Full Text] [Related]
4. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
[TBL] [Abstract][Full Text] [Related]
5. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components.
Timor-Tritsch IE; Foley CE; Brandon C; Yoon E; Ciaffarrano J; Monteagudo A; Mittal K; Boyd L
Ultrasound Obstet Gynecol; 2019 Sep; 54(3):395-402. PubMed ID: 30950132
[TBL] [Abstract][Full Text] [Related]
6. Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; D'argent Mathieu E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101966. PubMed ID: 33144266
[TBL] [Abstract][Full Text] [Related]
7. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
Int J Gynecol Pathol; 2006 Jan; 25(1):83-9. PubMed ID: 16306790
[TBL] [Abstract][Full Text] [Related]
8. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Short Text].
Bourdel N; Huchon C; Cendos AW; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chéreau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):223-235. PubMed ID: 32004780
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.
Okumura T; Muronosono E; Tsubuku M; Terao Y; Takeda S; Maruyama M
J Ovarian Res; 2018 Sep; 11(1):77. PubMed ID: 30176911
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
11. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
Vasconcelos I; de Sousa Mendes M
Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
[TBL] [Abstract][Full Text] [Related]
12. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
Vasconcelos I; Darb-Esfahani S; Sehouli J
BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
[TBL] [Abstract][Full Text] [Related]
13. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
14. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior.
Ronnett BM; Kajdacsy-Balla A; Gilks CB; Merino MJ; Silva E; Werness BA; Young RH
Hum Pathol; 2004 Aug; 35(8):949-60. PubMed ID: 15297962
[TBL] [Abstract][Full Text] [Related]
15. Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.
Hada T; Miyamoto M; Ishibashi H; Kawauchi H; Soyama H; Matsuura H; Sakamoto T; Kakimoto S; Aoyama T; Iwahashi H; Suzuki R; Tsuda H; Takano M
In Vivo; 2020; 34(3):1341-1346. PubMed ID: 32354928
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Recurrent Mucinous Borderline Ovarian Tumor with Aromatase Inhibitor.
Stambough KC; Muscal JA; Edwards CL; Dietrich JE
J Pediatr Adolesc Gynecol; 2020 Oct; 33(5):610-612. PubMed ID: 32251836
[TBL] [Abstract][Full Text] [Related]
17. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
Matsuo K; Machida H; Mandelbaum RS; Grubbs BH; Roman LD; Sood AK; Gershenson DM
Gynecol Oncol; 2019 May; 153(2):230-237. PubMed ID: 30797590
[TBL] [Abstract][Full Text] [Related]
18. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiology and Risk Factors of Relapse, Follow-up and Interest of a Completion Surgery].
Margueritte F; Sallee C; Lacorre A; Gauroy E; Larouzee E; Chereau E; De La Motte Rouge T; Koskas M; Gauthier T
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):248-259. PubMed ID: 32004784
[TBL] [Abstract][Full Text] [Related]
19. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
20. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
